STOCK TITAN

Verve Therapeutics, Inc. - VERV STOCK NEWS

Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.

Overview of Verve Therapeutics, Inc. (Nasdaq: VERV)

Verve Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a transformative approach to the treatment of cardiovascular diseases through innovative genetic medicines. Leveraging advancements in gene editing and human genetics, Verve aims to shift the paradigm of cardiovascular care from chronic management to single-course, durable therapies. The company's mission is to address the root causes of atherosclerotic cardiovascular disease (ASCVD) by targeting key genetic drivers such as LDL cholesterol, remnant cholesterol, and lipoprotein(a) [Lp(a)].

Core Technology and Therapeutic Platform

At the heart of Verve's innovation is its utilization of base editing, a precise gene editing technology designed to make targeted, permanent changes to specific genetic sequences. This technology is integrated with Verve's proprietary GalNAc-LNP delivery system, enabling efficient and targeted delivery of gene-editing components to liver cells, where cholesterol metabolism is regulated. By permanently silencing disease-driving genes like PCSK9 and ANGPTL3, Verve's therapies aim to achieve lifelong cholesterol reduction after a single intravenous infusion.

Pipeline and Key Programs

Verve's clinical pipeline includes three lead programs:

  • VERVE-102: A gene-editing medicine targeting the PCSK9 gene to lower LDL cholesterol. It is being developed for heterozygous familial hypercholesterolemia (HeFH) and patients with established ASCVD who remain at high risk despite standard therapies.
  • VERVE-201: Focused on inactivating the ANGPTL3 gene, this program addresses refractory hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH), conditions characterized by persistently high LDL cholesterol.
  • VERVE-301: A preclinical candidate targeting the LPA gene to reduce lipoprotein(a) levels, a genetically validated risk factor for ASCVD and other cardiovascular conditions.

Market Position and Competitive Landscape

Operating within the rapidly evolving field of genetic medicines, Verve Therapeutics is uniquely positioned as one of the first companies to focus exclusively on cardiovascular diseases. Its differentiation lies in its single-course gene editing approach, which contrasts with traditional chronic therapies that require lifelong patient adherence. Key competitors include other gene-editing firms like Intellia Therapeutics and CRISPR Therapeutics, though Verve's cardiovascular focus and proprietary delivery systems set it apart.

Challenges and Opportunities

Verve faces significant challenges, including stringent regulatory scrutiny, the need to demonstrate long-term safety and efficacy, and competition from both established pharmaceutical companies and emerging biotechs. However, its robust pipeline, strategic collaborations (notably with Eli Lilly), and focus on high unmet medical needs provide a strong foundation for growth and innovation. The company's ability to address safety concerns, such as those observed in early trials of VERVE-101, will be critical to its success.

Conclusion

Verve Therapeutics represents a bold step forward in the treatment of cardiovascular diseases, combining cutting-edge gene editing technologies with a focus on single-course, lifelong solutions. As it advances its clinical programs and navigates the complexities of the biotechnology landscape, Verve is poised to make a significant impact on the lives of patients with genetic cardiovascular risks.

Rhea-AI Summary

Verve Therapeutics announced the dosing of the first patient in the Heart-2 Phase 1b clinical trial evaluating VERVE-102, an investigational in vivo base editing medicine designed to reduce blood low-density lipoprotein cholesterol. The trial is enrolling patients with heterozygous familial hypercholesterolemia or premature coronary artery disease. VERVE-102 aims to permanently inactivate the PCSK9 gene in the liver, providing sustained reductions in LDL-C levels after a single treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
-
Rhea-AI Summary

Verve Therapeutics granted equity awards to ten new employees under the company's 2024 Inducement Stock Incentive Plan. The employees received stock options and restricted stock units, totaling 64,200 shares and 56,100 RSUs. The options have an exercise price of $6.01 per share and will vest over four years, while the RSUs will vest annually over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Verve Therapeutics announces updates from the Heart-1 Phase 1b clinical trial of VERVE-101, demonstrating significant LDL-C reduction of up to 73% at 0.45 mg/kg dose. However, enrollment in the trial is paused due to observed laboratory abnormalities in the sixth participant. Verve is prioritizing the development of VERVE-102, with clearance for the Heart-2 clinical trial expected in 2Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.95%
Tags
none
Rhea-AI Summary
Verve Therapeutics granted equity awards to six new employees under the 2024 Inducement Stock Incentive Plan. The awards include stock options for 91,200 shares and 45,800 restricted stock units, with an exercise price of $13.28 per share. The options have a 10-year term and will vest over four years, while the RSUs will vest annually over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Summary
Verve Therapeutics grants equity awards to new employees under the 2024 Inducement Stock Incentive Plan, with 16,300 RSUs vested over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
Rhea-AI Summary
Verve Therapeutics reports pipeline updates and financial results for Q4 2023, with $624 million in cash, proof-of-concept data for VERVE-101, and upcoming clinical trials for PCSK9 and ANGPTL3 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.47%
Tags
Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The company is pioneering a new approach to cardiovascular disease with single-course gene editing medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics (VERV) to Present at J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has successfully closed an underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, resulting in total gross proceeds of approximately $143.8 million. Additionally, the company announced the closing of a private placement of 2,296,317 shares of its common stock to Eli Lilly and Company, at a price per share equal to the public offering price, totaling approximately $23.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million. In addition, Verve has agreed to sell 2,296,317 shares of its common stock to Eli Lilly and Company in a private placement, resulting in aggregate gross proceeds of approximately $148.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags

FAQ

What is the current stock price of Verve Therapeutics (VERV)?

The current stock price of Verve Therapeutics (VERV) is $6.61 as of March 6, 2025.

What is the market cap of Verve Therapeutics (VERV)?

The market cap of Verve Therapeutics (VERV) is approximately 581.6M.

What does Verve Therapeutics specialize in?

Verve Therapeutics specializes in developing single-course gene editing therapies to address genetic drivers of cardiovascular diseases, such as LDL cholesterol and lipoprotein(a).

How does Verve's technology work?

Verve uses base editing, a precise gene editing technology, combined with its proprietary GalNAc-LNP delivery system to target and permanently silence disease-driving genes in liver cells.

What are Verve's main clinical programs?

Verve's key programs include VERVE-102 for LDL cholesterol reduction (PCSK9), VERVE-201 for refractory hypercholesterolemia (ANGPTL3), and VERVE-301 targeting lipoprotein(a) (LPA).

What differentiates Verve Therapeutics from its competitors?

Verve is uniquely focused on cardiovascular diseases and offers single-course gene editing therapies, contrasting with traditional chronic treatments that require lifelong adherence.

Who are Verve Therapeutics' collaborators?

Verve collaborates with leading organizations, including Eli Lilly, to advance its research and development programs targeting genetic cardiovascular risks.

What challenges does Verve face in its development process?

Key challenges include regulatory scrutiny, demonstrating long-term safety and efficacy, and managing competition from other gene-editing and pharmaceutical companies.

What is the significance of Verve's GalNAc-LNP delivery system?

The GalNAc-LNP system enhances the targeted delivery of gene-editing components to liver cells, improving the precision and efficacy of Verve's therapies.

What diseases are targeted by Verve's therapies?

Verve targets genetic drivers of atherosclerotic cardiovascular disease (ASCVD), including LDL cholesterol, remnant cholesterol, and lipoprotein(a).

What is the market potential for Verve's therapies?

Verve's therapies address high unmet needs in cardiovascular care, offering potential solutions for millions of patients with genetic risk factors for heart disease.

Where is Verve Therapeutics headquartered?

Verve Therapeutics is headquartered in Cambridge, Massachusetts.
Verve Therapeutics, Inc.

Nasdaq:VERV

VERV Rankings

VERV Stock Data

581.61M
84.27M
5.29%
97.97%
17.47%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON